ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Vivek Jain also recently made the following trade(s):
- On Monday, December 2nd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00.
- On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00.
ICU Medical Stock Up 1.8 %
NASDAQ ICUI traded up $2.81 during trading on Thursday, reaching $157.98. 208,164 shares of the company’s stock were exchanged, compared to its average volume of 269,089. The firm has a market capitalization of $3.87 billion, a PE ratio of -34.57 and a beta of 0.62. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company’s fifty day simple moving average is $164.91 and its 200-day simple moving average is $155.49. ICU Medical, Inc. has a fifty-two week low of $86.80 and a fifty-two week high of $196.26.
Institutional Trading of ICU Medical
Wall Street Analyst Weigh In
ICUI has been the topic of several recent research reports. Raymond James boosted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.67.
View Our Latest Stock Report on ICU Medical
About ICU Medical
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Recommended Stories
- Five stocks we like better than ICU Medical
- How to Use Stock Screeners to Find Stocks
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Bank Stocks – Best Bank Stocks to Invest In
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.